Table 1.
Patient characteristics and demographics.
| Patient Characteristic | Number (%) |
|---|---|
| Age at TARE | |
| Median Range |
58 (24–83) |
| Sex | |
| Male Female |
14 (40%) 21 (60%) |
| Baseline ECOG Performance Status | |
| 0 1 2 |
16 (45.7%) 13 (37.2%) 6 (17.1%) |
| Primary Site | |
| Retroperitoneum Liver Uterus Extremities Lung Stomach Other |
9 (25.7%) 7 (20%) 4 (11.4%) 3 (8.6%) 2 (5.7%) 2 (5.7%) 8 (22.9%) |
| Histotype | |
| Leiomyosarcoma Spindle Cell Sarcoma Hemangiopericytoma Hepatic Epithelioid Hemangioendothelioma Gastro-Intestinal Stromal Tumor Angiosarcoma Rhabdomyosarcoma Liposarcoma |
20 (57.1%) 4 (11.4%) 3 (8.6%) 2 (5.7%) 2 (5.7%) 2 (5.7%) 1 (2.9%) 1 (2.9%) |
| Baseline MELD | |
| Median Range |
8 (6–19) |
| Baseline Child-Turcotte-Pugh Class | |
| Class A Class B |
27 (77.1%) 8 (22.9%) |
| Baseline ALBI grade | |
| Grade 1 Grade 2–3 |
13 (37.1%) 22 (62.9%) |
| Primary Metastases | |
| Yes No |
16 (45.7%) 19 (54.3%) |
| Extrahepatic Disease | |
| Yes No |
22 (62.9%) 13 (37.1%) |
| Chemotherapy Pre-TARE | |
| Yes No |
27 (77.1%) 8 (22.9%) |
| Liver Surgery Pre-TARE | |
| Yes No |
9 (25.7%) 26 (74.3%) |
| Radiotherapy Pre-TARE | |
| Yes No |
16 (45.7%) 19 (54.3%) |
| Liver Involvement | |
| Bilobar Single lobe |
29 (82.8%) 6 (17.1%) |
| Baseline Liver Volume | |
|
1.5 L 1.5 L |
25 (71.4%) 10 (28.6%) |
TARE, trans-arterial radioembolization; ECOG, Eastern Cooperative Oncology Groups; ALBI, albumin–bilirubin; MELD, Model for End-Stage Liver Disease.